Kinase News and Research

RSS

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.

29 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Necrotising autoimmune myopathy requires early, aggressive treatment

Researchers call for the prompt recognition of necrotising autoimmune myopathy and aggressive early treatment with a combination of intravenous immune globulin, corticosteroids and a steroid-sparing agent for 3 months.

27 Jul 2015

Biologists identify genetic mechanisms behind anti-inflammatory impact of cortisone

There's no time to lose when an emergency doctor diagnoses „Shock lung!" at the accident scene. What physicians know as "acute lung injury" (ALI) otherwise leads to death by suffocation without immediate treatment.

25 Jul 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

Bosutinib resistance linked to ABCB1 transporter

Resistance to the tyrosine kinase inhibitor bosutinib may be mediated by overexpression of the efflux transporter ABCB1, scientists suggest.

24 Jul 2015

Rare BCR-ABL fusions highlighted in CML

Chronic myeloid leukaemia patients with rare BCR-ABL fusions may be missed by quantitative polymerase chain reaction, research suggests.

24 Jul 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.

22 Jul 2015

Study reveals potential new therapeutic target for depression treatment

Increasing the levels of a signaling molecule found in the brain can positively alter response to stress, revealing a potential new therapeutic target for treatment of depression, UT Southwestern Medical Center researchers said.

22 Jul 2015

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

15 Jul 2015

Single molecule appears to be central regulator driving cancer metastasis

Cancer is a disease of cell growth, but most tumors only become lethal once they metastasize or spread from their first location to sites throughout the body. For the first time, researchers at Thomas Jefferson University in Philadelphia report a single molecule that appears to be the central regulator driving metastasis in prostate cancer.

14 Jul 2015

Researchers discover new mechanism that regulates size of human cells

Every cell in the human body has to be a particular size in order to function correctly. The research group led by Markus Hengstschläger of the Institute for Medical Genetics at the Medical University of Vienna has now discovered a new mechanism that regulates cell size.

14 Jul 2015

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN N.V. today received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca's IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).

From QIAGEN Manchester Limited 14 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

LUX-Lung 8 supports afatinib in squamous NSCLC

Compared with erlotinib, treatment with afatinib leads to outcomes in previously treated patients with advanced squamous non-small-cell lung cancer, suggest the results of a head-to-head trial.

8 Jul 2015

Discovery could pave way to new treatments for malaria

Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease.

7 Jul 2015

Umeå University researchers capture and describe 'invisible' protein structure

A research group at Umeå University in Sweden has managed to capture and describe a protein structure that, until now, has been impossible to study. The discovery lays the base for developing designed enzymes as catalysts to new chemical reactions for instance in biotechnological applications.

3 Jul 2015

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.

2 Jul 2015

Kinase News and Research

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Necrotising autoimmune myopathy requires early, aggressive treatment

Biologists identify genetic mechanisms behind anti-inflammatory impact of cortisone

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Bosutinib resistance linked to ABCB1 transporter

Rare BCR-ABL fusions highlighted in CML

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

Study reveals potential new therapeutic target for depression treatment

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Single molecule appears to be central regulator driving cancer metastasis

Researchers discover new mechanism that regulates size of human cells

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

LUX-Lung 8 supports afatinib in squamous NSCLC

Discovery could pave way to new treatments for malaria

Umeå University researchers capture and describe 'invisible' protein structure

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News